FDA Determines Regulatory Review Period for ADLYXIN Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of ADLYXIN, a human drug product, following a submission to the U.S. Patent and Trademark Office (USPTO). This determination is a result of the FDA's requirement to publish a notice as per the law.